Institutional members access full text with Ovid®

Share this article on:

CD4 cell counts at the third month of HAART may predict clinical failure

Monforte, Antonella d‚Arminioa; Testori, Valeriaa; Adorni, Fulviob; Castelnuovo, Barbaraa; Bini, Teresaa; Testa, Letiziaa; Moscatelli, GianCarlaa; Chiesa, Elisabettaa; Rusconi, Stefanoa; Abeli, Claraa; Sollima, Salvatorea; Musicco, Massimob; Meroni, Lucaa; Galli, Massimoa; Moroni, Mauroa

Clinical: Original Papers

Objective: To evaluate the influence of immunological and virological markers on clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen.

Design and methods: Observational study of 585 patients initiating HAART in a clinical setting. Clinical failure was defined as the occurrence of new or recurrent AIDS-defining events or death, and was analysed by means of intention-to-treat, univariate and multivariate analyses. An adjusted Cox regression model was used to evaluate the effect of 3-month CD4 cell counts on clinical outcome.

Results: Clinical failure occurred in 55 patients (9.4%) during a median follow-up of 483 days (range 33-1334 days): 45 new AIDS-defining events (ADEs) in 38, ADE recurrence in six, and death in 11. Twenty-four of the 45 new ADEs (53.4%) occurred during the first 3 months of HAART, and 11 of 45 (24.4%) in the presence of CD4 cell counts >200×106cells/l. The mean (median, range) CD4 counts were 144×106cells/l (128, 4-529) in patients with and 322×106cells/l (288, 14-1162) in patients without clinical failure (P<0.0001). Moreover, the proportion of patients with mean CD4 cell counts <200×106cells/l was higher in those experiencing subsequent clinical failure (χ2 test: 26.75; P<0.00001). Multivariate analysis showed that baseline CD4 cell counts <50×106cells/l and AIDS at enrolment predicted failure; after adjusting for 3-month CD4 cell counts, this marker was the only one independently associated with clinical failure (hazard risk, 4.79; 95% confidence interval, 1.40-16.47).

Conclusions: The 3-month immunological response is a reliable predictor of long-term clinical outcome.

From the aInstitute of Infectious and Tropical Diseases, University of Milan and bNational Research Council-Institute of Advanced Biomedical Technologies (CNR-ITBA), Milan, Italy.

Sponsorship: This study was supported by grants from National Institute of Health, AIDS Project 50A.0.10.1997

Correspondence to Antonella d‚Arminio Monforte, Institute of Infectious and Tropical Diseases, University of Milan, L Sacco Hospital, via GB Grassi, 74, 20157 Milan, Italy.

Received: 8 February 1999; revised: 17 May 1999; accepted: 27 May 1999.

© 1999 Lippincott Williams & Wilkins, Inc.